BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Mayo Clinic Laboratories invests in Pathology Asia Holdings and LifeStrands Genomics in Singapore

September 24, 2026 | News

Genomics is a central focus of the collaboration, delivered through LifeStrands Genomics



US-based Mayo Clinic Laboratories and Pathology Asia Holdings (PAH), based in Singapore, have announced a strategic investment and collaboration aimed at expanding access to advanced diagnostics and precision medicine across Southeast Asia, Australia and New Zealand.

Mayo Clinic Laboratories and PAH are deepening a long-term relationship that brings together Mayo's global clinical and diagnostic expertise with the regional healthcare network, capabilities and market knowledge of PAH and its genomics subsidiary, LifeStrands Genomics.

William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, has been appointed Scientific Adviser to PAH.

Genomics is a central focus of the collaboration, delivered through LifeStrands Genomics. Mayo Clinic Laboratories and LifeStrands Genomics will work together to broaden access to advanced molecular and genomic testing across Southeast Asia, Australia and New Zealand, with applications spanning the identification of genetic conditions, disease risk assessment, diagnosis, and treatment planning, enabling healthcare providers to integrate clinically relevant genomic insights into more personalised patient care.

LifeStrands Genomics will operate as "LifeStrands in collaboration with Mayo Clinic Laboratories" in certain markets, reflecting the organisations' shared commitment to expanding access to advanced genomic testing and precision medicine across the region.